Catalyst (CPRX) Is a Great Choice for 'Trend' Investors, Here's Why
Catalyst (CPRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma
FIRDAPSE continues to drive strong performance, with Q1 2025 revenue and EPS both beating analyst expectations significantly. Catalyst reaffirmed its 2025 FIRDAPSE revenue guidance of $355–$360 million, projecting 15–20% annual growth going forward. The company has penetrated about 25% of the $1.2 billion LEMS market, with further upside as cancer-associated LEMS remains underdiagnosed.
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeff Del Carmen - Executive Vice President, Chief Commercial Officer Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical and Regulatory Officer Conference Call Participants Asim Rana - Truist Securities Benjamin Paluch - Citi Investment Research Joel Beatty - Baird Charles Duncan - Cantor Fitzgerald Rohan Matur - Oppenheimer & Co. Inc. Jason Gerberry - Bank of America Global Research Felix Ampomah - Stephens & Co. Operator Good day everyone, and welcome to the Catalyst Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago.
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy?
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win
This IBD 50 holding holds top notch ratings amid a market downturn. The post Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win appeared first on Investor's Business Daily.
Strong Revenue, Drug Performance Lift Catalyst Shares
Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX).
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts
Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven by expanding drug distribution, increasing dosages, and acquiring additional drugs, while downside risk is limited by strong cash flow and exclusivity runways. The base case is very realistic, offering an attractive asymmetric trade payoff with a potential 40% upside, despite risks associated with acquisition-dependent revenue growth.
